Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Total Non-Current Liabilities (2016 - 2025)

Haemonetics has reported Total Non-Current Liabilities over the past 16 years, most recently at $1.5 billion for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 1.21% year-over-year to $1.5 billion; the TTM value through Dec 2025 reached $1.5 billion, down 1.21%, while the annual FY2025 figure was $1.6 billion, 34.58% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $1.5 billion at Haemonetics, down from $1.5 billion in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $1.6 billion in Q1 2025 and troughed at $976.2 million in Q3 2022.
  • A 5-year average of $1.2 billion and a median of $1.1 billion in 2022 define the central range for Total Non-Current Liabilities.
  • On a YoY basis, Total Non-Current Liabilities climbed as much as 104.19% in 2022 and fell as far as 4.29% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $1.0 billion in 2021, then grew by 1.26% to $1.0 billion in 2022, then grew by 15.33% to $1.2 billion in 2023, then increased by 29.94% to $1.5 billion in 2024, then dropped by 1.21% to $1.5 billion in 2025.
  • Business Quant data shows Total Non-Current Liabilities for HAE at $1.5 billion in Q4 2025, $1.5 billion in Q3 2025, and $1.5 billion in Q2 2025.